
Getty Images
News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (...

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT - a new radiation machine developed to treat all stages of cancer.
News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) for...
News | Molecular Imaging | May 28, 2020
May 27, 2020 — PETNET Solutions, Inc., a Siemens Healthineers company, and Zionexa USA, a wholly owned subsidiary of...

Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function. Image courtesy of YaleNews.
News | PET Imaging | May 14, 2020
May 14, 2020 — New imaging technology allows scientists to see the widespread loss of brain synapses in early stages of...
News | Coronavirus (COVID-19) | April 30, 2020
April 30, 2020 — The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and...
Videos | Coronavirus (COVID-19) | April 18, 2020
Stephen Bloom, M.D., FASNC, director of noninvasive cardiology (cardiac CT, nuclear cardiology and echocardiography) at...

U.S. Army Spc. Jonathon Hyde and Spc. Casymn Harrison from the 1434th Engineer Company, Grayling, Mich., Michigan National Guard, prepare patient rooms at TCF Regional Care Center in Detroit in advance of receiving COVID-19 patients, April 9, 2020. The TCF Center in Detroit has been converted into a 970-bed alternative care facility for COVID-19 patients by the Federal Emergency Management Agency, in partnership with the U.S. Army Corps of Engineers and Michigan National Guard. (Photo courtesy of U.S. Air National Guard photo by Master Sgt. Scott Thompson)
Feature | Coronavirus (COVID-19) | April 15, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), the...

Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group. Image courtesy of Eric Berg, University of California, Davis, CA
News | PET Imaging | April 10, 2020
April 10, 2020 — Combining 89Zr-labeled antibodies with total-body positron emission tomography (PET) has extended the...
News | PET Imaging | April 09, 2020
April 9, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (...
Videos | Coronavirus (COVID-19) | April 04, 2020
Hicham Skali, M.D., a staff cardiologist and member of the Non-invasive Cardiovascular Imaging Program at Brigham and...
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear...
Videos | Coronavirus (COVID-19) | March 27, 2020
Regina Druz, M.D., FASNC, a member of the American Society of Nuclear Cardiology (ASNC) Board of Directors, chairwomen...

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.
News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution positron emission tomography/computed tomography (PET/CT)...
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “Cyclotrons used in Nuclear Medicine Report &...
February 28, 2020 — MR Solutions will be displaying its latest dry magnet 3T to 9.4T preclinical, multi-modality MRI (...

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of...

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced a...
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment market in the Asia-Pacific (APAC) region is expected to grow at a...

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)
News | Molecular Imaging | February 06, 2020
February 6, 2020 — On Target Laboratories Inc., a privately held biotechnology company developing the use of Purdue...

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria
News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful breast cancer biomarkers that indicate the...